4-methylcoumarin-7-o-sulfamate has been researched along with Breast-Neoplasms* in 4 studies
4 other study(ies) available for 4-methylcoumarin-7-o-sulfamate and Breast-Neoplasms
Article | Year |
---|---|
Development of Sulfamoylated 4-(1-Phenyl-1
Topics: Animals; Breast Neoplasms; Enzyme Inhibitors; Female; Humans; MCF-7 Cells; Mice; Phenol; Steryl-Sulfatase; Structure-Activity Relationship | 2022 |
Synthesis and biological evaluation of fluorinated N-benzoyl and N-phenylacetoyl derivatives of 3-(4-aminophenyl)-coumarin-7-O-sulfamate as steroid sulfatase inhibitors.
In the present work, we report convenient methods for the synthesis of 3-(4-aminophenyl)-coumarin-7-O-sulfamate derivatives N-acylated with fluorinated analogues of benzoic or phenylacetic acid as steroid sulfatase (STS) inhibitors. The design of these potential STS inhibitors was supported by molecular modeling techniques. Additionally, computational docking methods were used to determine the binding modes of the synthesized inhibitors and to identify potential interactions between inhibitors and amino acid residues located in the active site of STS. The inhibitory effects of the synthesized compounds were tested on STS isolated from human placenta and against estrogen receptor-(ER)-positive MCF-7 and T47D cells, as well as ER-negative MDA-MB-231 and SkBr3 cancer cell lines. In the course of our investigation, compounds 6c and 6j demonstrated the highest inhibitory effect in enzymatic STS assays, both with IC Topics: Breast Neoplasms; Coumarins; Enzyme Inhibitors; Female; Halogenation; Humans; Placenta; Pregnancy; Receptors, Estrogen; Steryl-Sulfatase; Structure-Activity Relationship; Sulfonamides; Tumor Cells, Cultured | 2017 |
Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health.
In 1994, following work from this laboratory, it was reported that estrone-3-O-sulfamate irreversibly inhibits a new potential hormone-dependent cancer target steroid sulfatase (STS). Subsequent drug discovery projects were initiated to develop the core aryl O-sulfamate pharmacophore that, over some 20 years, have led to steroidal and nonsteroidal drugs in numerous preclinical and clinical trials, with promising results in oncology and women's health, including endometriosis. Drugs have been designed to inhibit STS, e.g., Irosustat, as innovative dual-targeting aromatase-steroid sulfatase inhibitors (DASIs) and as multitargeting agents for hormone-independent tumors, such as the steroidal STX140 and nonsteroidal counterparts, acting inter alia through microtubule disruption. The aryl sulfamate pharmacophore is highly versatile, operating via three distinct mechanisms of action, and imbues attractive pharmaceutical properties. This Perspective gives a personal view of the work leading both to the therapeutic concepts and these drugs, their current status, and how they might develop in the future. Topics: Animals; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Drug Discovery; Endometriosis; Estrone; Female; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Steryl-Sulfatase; Sulfonic Acids; Tubulin Modulators | 2015 |
Active site directed inhibition of estrone sulfatase by nonsteroidal coumarin sulfamates.
Topics: Binding Sites; Breast Neoplasms; Coumarins; Enzyme Inhibitors; Humans; Microsomes; Placenta; Sulfatases; Sulfonamides; Tumor Cells, Cultured | 1996 |